Literature DB >> 8636751

Attitudes of 47 mothers of pediatric oncology patients toward genetic testing for cancer predisposition.

A F Patenaude1, L Basili, D L Fairclough, F P Li.   

Abstract

PURPOSE: To assess attitudes toward testing for cancer susceptibility genes, we interviewed mothers of pediatric oncology patients about their cancer causation theories, interest in hypothetical predisposition testing for themselves and their healthy children, and anticipated impact of testing. PATIENTS AND METHODS: The subjects were 47 mothers of two or more living children, one of whom was 6 to 24 months postdiagnosis of cancer. Potential risks and benefits of hypothetical genetic predisposition testing for cancer susceptibility were described. A semistructured interview assessed the following: (1) recall of discussions with the pediatric oncologist about the possible role of heredity in causing the child's cancer; (2) mothers' personal theories of the etiology of their child's cancer; (3) family cancer history; (4) interest in genetic predisposition testing for themselves and unaffected (cancer-free) children; and (5) expected sequelae of testing.
RESULTS: If genetic cancer predisposition tests were available, 51% of mothers would test themselves and 42% would test healthy children, even with no medical benefit. With established medical benefit, an additional 36% of mothers would seek testing for themselves and another 49% would test their healthy children. Interest in cancer predisposition testing among mothers extended far beyond those with significant family histories of cancer. Most mothers would consider minor children's wishes in the decision about testing and would tell children under age 18 their test results.
CONCLUSION: As increasing numbers of cancer susceptibility genes are identified, parents of pediatric oncology patients may be receptive to opportunities to test themselves and their healthy children. Counseling will be important to aid in decisions about testing. Research is essential to evaluate the long-term impact of predisposition testing.

Entities:  

Keywords:  Empirical Approach; Genetics and Reproduction

Mesh:

Year:  1996        PMID: 8636751     DOI: 10.1200/JCO.1996.14.2.415

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

1.  Genetic knowledge and attitudes of parents of children with congenital heart defects.

Authors:  Sara M Fitzgerald-Butt; Jennifer Klima; Kelly Kelleher; Deena Chisolm; Kim L McBride
Journal:  Am J Med Genet A       Date:  2014-09-24       Impact factor: 2.802

2.  Who Is at Risk for Psychological Distress in Genetic Testing Programs for Hereditary Cancer Disorders?

Authors:  F J Grosfeld; C J Lips; F A Beemer; H F Ten Kroode
Journal:  J Genet Couns       Date:  2000-06       Impact factor: 2.537

Review 3.  Ethical perspectives on translational pharmacogenetic research involving children.

Authors:  Parvaz Madadi
Journal:  Paediatr Drugs       Date:  2015-02       Impact factor: 3.022

4.  Brief assessment of parents' attitudes toward testing minor children for hereditary breast/ovarian cancer genes: development and validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS).

Authors:  Beth N Peshkin; Tiffani A DeMarco; Judy E Garber; Heiddis B Valdimarsdottir; Andrea F Patenaude; Katherine A Schneider; Marc D Schwartz; Kenneth P Tercyak
Journal:  J Pediatr Psychol       Date:  2008-04-01

5.  Parental knowledge and attitudes toward hypertrophic cardiomyopathy genetic testing.

Authors:  Sara M Fitzgerald-Butt; Lindsey Byrne; Cynthia A Gerhardt; Kathryn Vannatta; Timothy M Hoffman; Kim L McBride
Journal:  Pediatr Cardiol       Date:  2009-12-01       Impact factor: 1.655

6.  Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients.

Authors:  Sarah Scollon; Katie Bergstrom; Robin A Kerstein; Tao Wang; Susan G Hilsenbeck; Uma Ramamurthy; Richard A Gibbs; Christine M Eng; Murali M Chintagumpala; Stacey L Berg; Laurence B McCullough; Amy L McGuire; Sharon E Plon; D Williams Parsons
Journal:  Genome Med       Date:  2014-09-17       Impact factor: 11.117

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.